Journal article · 2026 · Open access

Clinical–biological Alzheimer's disease stage concordance: insights from cohorts and autopsy data

Lydia Trudel, Joseph Therriault, Arthur C. Macedo, Seyyed Ali Hosseini, Jaime Fernández Arias, Tevy Chan, Nesrine Rahmouni, Gleb Bezgin, Cécile Tissot, Marcel S. Woo, Étienne Aumont, Yansheng Zheng and 15 more

Brain, 149(8), 2803–2815 · Published 17 January 2026 · DOI 10.1093/brain/awag018

Open full textCite this paper

In brief

“Clinical–biological Alzheimer's disease stage concordance: insights from cohorts and autopsy data” is a 2026 journal article by Lydia Trudel and 26 co-authors, published in Brain. OpenAlex counts 10 citations as of 18 November 2026, which puts it in the top 2% of works published in 2026 by citations. It is open access under a CC BY-NC licence: the full text is free to read at Brain.

Citations
10
Most cited in
2026 (10)
Field-weighted impact
26.84
References
71
Authors
27

Abstract

Alzheimer's disease (AD) is defined by its characteristic neuropathological changes, which allow for diagnosis and assessment of severity. Recently, the Alzheimer's Association proposed a framework to stage AD biologically based on tau-PET. Furthermore, the framework hypothesizes a degree of alignment between biological AD severity and clinical symptom severity. We aimed to investigate the concordance between clinical and biological stages of AD and explore factors contributing to discordance using in vivo and post-mortem neuropathological data. Data from 768 amyloid-β-positive individuals were drawn from four observational cross-sectional in vivo cohorts (TRIAD, ADNI, HABS-HD and SCAN) in addition to a post-mortem autopsy dataset from the National Alzheimer's Coordinating Center (NACC; n = 3188). All in vivo participants had tau-PET imaging, clinical diagnosis and neurobehavioural assessments. Participants were assigned a biological AD stage based on their tau-PET scan according to the Alzheimer's Association revised criteria stages. The autopsy dataset included individuals with moderate-to-frequent neuritic plaques (CERAD scores 2-3), along with pre-mortem clinical and neurobehavioural data. Clinical-biological concordance was quantified using squared-weighted Cohen's κ. Ordinal and linear regression models assessed associations between biological stage and clinical severity (Clinical Dementia Rating-Sum of Boxes, Mini-Mental State Examination), adjusting for age, sex and cohort. Post-mortem analyses evaluated the impact of comorbid neuropathologies on clinical-biological discordance using adjusted odds ratios and ordinal regression. Overall concordance between clinical and biological AD staging was moderate (Cohen's κ = 0.52, P < 0.001). Approximately 70% of individuals classified as cognitively unimpaired or with dementia exhibited biological stages consistent with their clinical diagnoses. In contrast, transitional decline and mild cognitive impairment groups were more heterogeneous. Notably, 25% of amyloid-β-positive individuals with mild cognitive impairment demonstrated no detectable tau-PET abnormality. Nonetheless, advanced tau-PET stage was reliably associated with clinical impairment. In the NACC autopsy dataset, nearly all individuals with a more severe clinical stage than their proposed biological stage exhibited comorbid neuropathologies, including frontotemporal lobar degeneration (FTLD)-TDP-43, FTLD-tau, Lewy bodies, limbic-predominant age-related TDP-43 encephalopathy (LATE) and cerebrovascular disease. The number of comorbid pathologies was strongly associated with increased odds of clinical dementia (t = 8.45, P < 0.001). Although there is moderate agreement between clinical and biological stages of AD across the entire disease spectrum, strong agreement is found in clinically unimpaired and dementia stages. Comparison of clinical and biological AD stages provides a framework for understanding the large contributions of non-AD neurodegenerative diseases to dementia in amyloid-β-positive individuals. Our results have important implications for clinical trial recruitment strategies and highlight the urgent need for biomarkers for non-AD pathological processes.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Trudel, L., Therriault, J., Macedo, A. C., Hosseini, S. A., Arias, J. F., Chan, T., Rahmouni, N., Bezgin, G., Tissot, C., Woo, M. S., Aumont, É., Zheng, Y., Hall, B. J., Oliva-Lopez, D., Mitchell, S. W., Hopewell, R., Hsiao, C. H.-H., Toga, A. W., Braskie, M. N., . . . Rosa‐Neto, P. (2026). Clinical–biological Alzheimer's disease stage concordance: insights from cohorts and autopsy data. Brain, 149(8), 2803–2815. https://doi.org/10.1093/brain/awag018

MLA 9

Trudel, Lydia, et al. “Clinical–biological Alzheimer's disease stage concordance: insights from cohorts and autopsy data.” Brain, vol. 149, no. 8, 2026, pp. 2803–2815. https://doi.org/10.1093/brain/awag018.

Chicago

Trudel, Lydia, Joseph Therriault, Arthur C. Macedo, Seyyed Ali Hosseini, Jaime Fernández Arias, Tevy Chan, Nesrine Rahmouni, et al. 2026. “Clinical–biological Alzheimer's disease stage concordance: insights from cohorts and autopsy data.” Brain 149 (8): 2803–2815. https://doi.org/10.1093/brain/awag018.

Harvard

Trudel, L. et al. (2026) ‘Clinical–biological Alzheimer's disease stage concordance: insights from cohorts and autopsy data’, Brain, 149(8), pp. 2803–2815. doi:10.1093/brain/awag018.

IEEE

L. Trudel et al., “Clinical–biological Alzheimer's disease stage concordance: insights from cohorts and autopsy data,” Brain, vol. 149, no. 8, pp. 2803–2815, 2026, doi: 10.1093/brain/awag018.

BibTeX

@article{trudel2026clinical,
  title     = {{Clinical–biological Alzheimer's disease stage concordance: insights from cohorts and autopsy data}},
  author    = {Trudel, Lydia and Therriault, Joseph and Macedo, Arthur C. and Hosseini, Seyyed Ali and Arias, Jaime Fernández and Chan, Tevy and Rahmouni, Nesrine and Bezgin, Gleb and Tissot, Cécile and Woo, Marcel S. and Aumont, Étienne and Zheng, Yansheng and Hall, Brandon J. and Oliva-Lopez, Delphine and Mitchell, Stuart William and Hopewell, Robert and Hsiao, Chris Hung-Hsin and Toga, Arthur W. and Braskie, Meredith N. and Meeker, Karin L. and Soucy, Jean‐Paul and Guiot, Marie-Christine and Gauthier, Serge G. and Vitali, Paolo and O’Bryant, Sid E. and Pascoal, Tharick Ali and Rosa‐Neto, Pedro},
  journal   = {Brain},
  year      = {2026},
  volume    = {149},
  number    = {8},
  pages     = {2803--2815},
  doi       = {10.1093/brain/awag018},
  url       = {https://doi.org/10.1093/brain/awag018}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research

  • Alzheimer's disease
  • tau PET
  • amyloid-beta
  • mild cognitive impairment
  • frontotemporal lobar degeneration
  • Lewy bodies
  • Lates
  • cerebrovascular disease

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Trudel, L., Therriault, J., Macedo, A. C., Hosseini, S. A., Arias, J. F., Chan, T., Rahmouni, N., Bezgin, G., Tissot, C., Woo, M. S., Aumont, É., Zheng, Y., Hall, B. J., Oliva-Lopez, D., Mitchell, S. W., Hopewell, R., Hsiao, C. H.-H., Toga, A. W., Braskie, M. N., . . . Rosa‐Neto, P. (2026). Clinical–biological Alzheimer's disease stage concordance: insights from cohorts and autopsy data. Brain, 149(8), 2803–2815. https://doi.org/10.1093/brain/awag018

How many times has this paper been cited?

10 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Brain: sign in and open the full text from this page.

Who wrote this paper?

Lydia Trudel, Joseph Therriault, Arthur C. Macedo, Seyyed Ali Hosseini, Jaime Fernández Arias, Tevy Chan, Nesrine Rahmouni, Gleb Bezgin, Cécile Tissot, Marcel S. Woo, Étienne Aumont, Yansheng Zheng and 15 more.

What is the DOI of this paper?

10.1093/brain/awag018, permanently at https://doi.org/10.1093/brain/awag018. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.